Prestige Consumer Healthcare (NYSE:PBH) Stock Rating Upgraded by Zacks Research

Prestige Consumer Healthcare (NYSE:PBH) was upgraded by investment analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Wednesday, Zacks reports.

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of Prestige Consumer Healthcare in a report on Tuesday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $67.67.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock opened at $44.68 on Wednesday. Prestige Consumer Healthcare has a fifty-two week low of $42.62 and a fifty-two week high of $71.07. The company has a market capitalization of $2.12 billion, a price-to-earnings ratio of 12.51, a PEG ratio of 1.44 and a beta of 0.34. The stock has a fifty day moving average of $50.06 and a two-hundred day moving average of $51.33. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.09. The business had revenue of $265.71 million for the quarter, compared to the consensus estimate of $253.02 million. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The business’s revenue was up 6.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. On average, analysts anticipate that Prestige Consumer Healthcare will post 4.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Large investors have recently added to or reduced their stakes in the business. Barrow Hanley Mewhinney & Strauss LLC purchased a new stake in Prestige Consumer Healthcare in the 2nd quarter valued at about $30,000. Versant Capital Management Inc boosted its position in shares of Prestige Consumer Healthcare by 47.9% in the second quarter. Versant Capital Management Inc now owns 726 shares of the company’s stock worth $34,000 after acquiring an additional 235 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in Prestige Consumer Healthcare by 69.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after purchasing an additional 236 shares during the period. Cornerstone Planning Group LLC purchased a new stake in Prestige Consumer Healthcare in the first quarter valued at approximately $44,000. Finally, Global Retirement Partners LLC acquired a new position in Prestige Consumer Healthcare during the second quarter worth approximately $80,000. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc (NYSE: PBH) is a consumer healthcare company that develops, markets and distributes over-the-counter (OTC) products and household health-care brands. Its portfolio includes products for eye care, oral care, gastrointestinal health, pain relief, respiratory health, women’s health, and other everyday health needs.

The company’s brands include Dramamine, Bonine, BC, Goody’s, Clear Eyes, TheraTears, Monistat, Summer’s Eve, Vagisil, Luden’s, Chloraseptic, Compound W, Fleet and Debrox.